Literature DB >> 19591991

Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium.

Mei Yu1, Jia-xin Yang, Ming Wu, Jing-he Lang, Zhen Huo, Keng Shen.   

Abstract

A retrospective study on 25 women (8 with endometrial carcinoma, 17 with severe endometrial atypical hyperplasia) under 35 years treated with progestin showed that six cases (75%) in the endometrial carcinoma (EC) group and 17 (100%) in the atypical hyperplasia (AH) group responded to the treatment, and among the 14 complete responders, 4 (40%) patients with AH had 7 pregnancies and 3 healthy deliveries. Given accurate pretreatment assessment, progestin therapy is a feasible management option to preserve fertility for young women with well-differentiated endometrial carcinoma or severe atypical hyperplasia of endometrium.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19591991     DOI： 10.1016/j.fertnstert.2009.06.013

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  12 in total

1.  All-cause mortality in young women with endometrial cancer receiving progesterone therapy.

Authors:  Maria P Ruiz; Yongmei Huang; June Y Hou; Ana I Tergas; William M Burke; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2017-08-24       Impact factor: 8.661

Review 2.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

3.  Endometrial Cancer Incidence in Patients With Atypical Endometrial Hyperplasia According to Mode of Management.

Authors:  Anas Barakat; Aemn Ismail; Supratik Chattopadhyay; Quentin Davies
Journal:  Cancer Diagn Progn       Date:  2022-09-03

4.  Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.

Authors:  Kuang-Tzu Huang; Savvas C Pavlides; Jon Lecanda; Stephanie V Blank; Khushbakhat R Mittal; Leslie I Gold
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

Review 5.  Preserving fertility in young patients with endometrial cancer: current perspectives.

Authors:  Eleftheria Kalogera; Sean C Dowdy; Jamie N Bakkum-Gamez
Journal:  Int J Womens Health       Date:  2014-07-29

Review 6.  Fertility-preservation in endometrial cancer: is it safe? Review of the literature.

Authors:  Márcia Mendonça Carneiro; Rívia Mara Lamaita; Márcia Cristina França Ferreira; Agnaldo Lopes Silva-Filho
Journal:  JBRA Assist Reprod       Date:  2016-12-01

7.  Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Authors:  Wataru Yamagami; Nobuyuki Susumu; Takeshi Makabe; Kensuke Sakai; Hiroyuki Nomura; Fumio Kataoka; Akira Hirasawa; Kouji Banno; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2018-01-02       Impact factor: 4.401

8.  Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis.

Authors:  Miaomiao Li; Tao Guo; Ran Cui; Ying Feng; Huimin Bai; Zhenyu Zhang
Journal:  Cancer Manag Res       Date:  2019-05-06       Impact factor: 3.602

9.  Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy.

Authors:  Junyu Chen; Dongyan Cao; Jiaxin Yang; Mei Yu; Huimei Zhou; Ninghai Cheng; Jinhui Wang; Ying Zhang; Peng Peng; Keng Shen
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

10.  Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.

Authors:  Erica Herrera Cappelletti; Jonas Humann; Rafael Torrejón; Pietro Gambadauro
Journal:  Hum Reprod Update       Date:  2022-02-28       Impact factor: 15.610
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.